The aims were to investigate the effect of intravenous infusions of the tumor necrosis factor-α (TNF-α) antibody infliximab on symptoms and signs of temporomandibular joint (TMJ) involvement in relation to effects on synovial fluid and plasma proinflammatory TNF-α, interleukin-1β (IL-1β) and interleukin-6 as well as antiinflam matory soluble TNF receptor II (TNF-sRII), interleukin-1 receptor antagonist (IL-1ra), soluble IL-1 receptor II (IL-1sRII) and interleukin-10 (IL-10) in patients with active rheumatoid arthritis (RA). Nineteen patients with TMJ involvement taking methotrexate were included in the study. TMJ and general joint pain intensity as well as pain on mandibular movements, tenderness to digital palpation, pressure pain threshold and maximum mouth-opening capacity were assessed in a clinical examination. The effect of infliximab was assessed after 2 and 14 or 22 weeks. TMJ synovial fluid and venous blood were collected for cytokine analysis at all occasions while determination of erythrocyte sedimentation rate and C-reactive protein were performed at baseline and at long-term follow-up only. Reduction of TMJ pain was associated with raised levels of synovial fluid TNF-sRII and IL-1sRII as well as raised plasma levels of IL-1ra and IL-10. Decreased erythrocyte sedimentation rate was associated with decreased tenderness to digital palpation. Reduced general joint pain intensity was associated with reduced plasma levels of IL-6 and C-reactive protein. In conclusion, systemic treatment with a combination of infliximab and methotrexate reduces TMJ pain in RA in association with an increase in anti-inflammatory cytokines and receptors in synovial fluid and plasma.

Keywords:
Cytokines, Infliximab, Temporomandibular joint, Rheumatoid arthritis, Pain
1.
Alstergren, P., C. Benavente, S. Kopp (2003) Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac Surg 61: 1171–1178.
2.
Alstergren, P., S. Kopp (1997) Pain and synovial fluid concentration of serotonin in arthritic temporomandibular joints. Pain 72: 137–143.
3.
Alstergren, P., S. Kopp, E. Theodorsson (1999) Synovial fluid sampling from the temporomandibular joint: sample quality criteria and levels of interleukin-1beta and serotonin. Acta Odontol Scand 57: 16–22.
4.
Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324.
5.
Charles, P., M.J. Elliott, D. Davis, A. Potter, J.R. Kalden, C. Antoni, F.C. Breedveld, J.S. Smolen, G. Eberl, K. deWoody, M. Feldmann, R.N. Maini (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163: 1521–1528.
6.
Dinarello, C.A. (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16: 457–499.
7.
Duff, G.W. (1994) Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 100: 9–19.
8.
Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Bijl (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110.
9.
Jouvenne, P., E. Vannier, C.A. Dinarello, P. Miossec (1998) Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 41: 1083–1089.
10.
Lipsky, P.E., D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, M. Weisman, P. Emery, M. Feldmann, G.R. Harriman, R.N. Maini (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–1602.
11.
Maini, R., E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, P. Lipsky (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932–1939.
12.
Maini, R.N., F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, T.F. Schaible, M. Feldmann (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563.
13.
Miller, L.C., E.A. Lynch, S. Isa, J.W. Logan, C.A. Dinarello, A.C. Steere (1993) Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis [see comments]. Lancet 341: 146–148.
14.
Moreland, L.W. (1999) Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 26: 7–15.
15.
Niedel, J., M. Schulze, J. Lindshau (1995) Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 44: 217–221.
16.
Nordahl, S., P. Alstergren, S. Kopp (2000) Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 58: 525–530.
17.
Rosengren, S., G.S. Firestein, D.L. Boyle (2003) Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 10: 1002–1010.
18.
Samols, D., A. Agrawal, I. Kushner (2002) Acute phase proteins; in Oppenheim, J.J., M. Feldmann (eds): Cytokine Reference. Amsterdam, Elsevier Science, pp 1–16.
19.
Taiwo, Y.O., J.D. Levine (1992) Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 48: 485–490.
20.
Tegelberg, A., S. Kopp (1987) Clinical findings in the stomatognathic system for individuals with rheumatoid arthritis and osteoarthrosis. Acta Odontol Scand 45: 65–75.
21.
van de Loo, A.A., O.J. Arntz, A.C. Bakker, P.L. van Lent, M.J. Jacobs, W.B. van den Berg (1995) Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 146: 239–249.
22.
Voog, U., P. Alstergren, S. Eliasson, E. Leibur, R. Kallikorm, S. Kopp (2004) Progression of radiographic changes in the temporomandibular joints of patients with rheumatoid arthritis in relation to inflammatory markers and mediators in the blood. Acta Odontol Scand 62: 7–13.
23.
Watkins, L.R., E.P. Wiertelak, L.E. Goehler, K.P. Smith, D. Martin, S.F. Maier (1994) Characterization of cytokine-induced hyperalgesia. Brain Res 654: 15–26.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.